Proteomic analysis in cancer research: Potential application in clinical use

Clinical and Translational Oncology

Volumn 8, Issue 4, 2006, Pages 250-261

  García Foncillas, Jesús ^a   Bandrés, Eva ^a   Zárate, Ruth ^a   Remírez, Natalia ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Cancer; Diagnostic tools; Proteomics

Indexed keywords

CANCER ANTIBODY; TUMOR MARKER; TUMOR PROTEIN;

AFFINITY CHROMATOGRAPHY; CHEMISTRY; CLASSIFICATION; COMPUTER PROGRAM; DNA MICROARRAY; EARLY DIAGNOSIS; GENE EXPRESSION PROFILING; GENETICS; HUMAN; IMAGE SUBTRACTION; IMMUNOLOGY; LABORATORY DIAGNOSIS; MASS SPECTROMETRY; METHODOLOGY; NEOPLASM; PROTEOMICS; REVIEW; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANTIBODIES, NEOPLASM; CHROMATOGRAPHY, AFFINITY; EARLY DIAGNOSIS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION PROFILING; HUMANS; MASS SPECTROMETRY; NEOPLASM PROTEINS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOMICS; SOFTWARE; SPECIMEN HANDLING; SUBTRACTION TECHNIQUE; TUMOR MARKERS, BIOLOGICAL;

EID: 33746811896     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02664935     Document Type: Article

References (81)

1. Ye B, Skates S, Mok SC, et al. Proteomicbased discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res. 2006;12:432-41.
2. Grossman HB, Soloway M, Messing E, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA. 2006;295:299-305.
3. Liu Y. Serum proteomic pattern analysis for early cancer detection. Technol Cancer Res Treat. 2006;5:61-6.
4. Maciel CM, Junqueira M, Paschoal ME, et al. Differential proteomic serum pattern of low molecular weight proteins expressed by adenocarcinoma lung cancer patients. J Exp Ther Oncol. 2005;5:31-8.
5. Wu H, Pan CL, Yao, YC, Chang SS, Li SL, Wu TF. Proteomic analysis of the effect of Antrodia camphorata extract on human lung cancer A549 cell. Proteomics. 2006;6: 826-35.
6. Vasilescu J, Smith JC, Ethier M, Figeys D. Proteomic analysis of ubiquitinated proteins from human MCF-7 breast cancer cells by immunoaffinity purification and mass spectrometry. J Proteome Res. 2005; 4:2192-200.
7. Rowell C, Carpenter DM, Lamartiniere CA. Chemoprevention of breast cancer, proteomic discovery of genistein action in the rat mammary gland. J Nutr. 2005;155: 2953S-9S.
8. Varambally S, Yu J, Laxman B, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell, 2005; 8:393-406.
9. Cheng AJ, Chen LC, Chien KY, et al. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin Chem. 2005;51: 2236-44.
10. Kong F, Nicole White C, Xiao X, et al. Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer. Gynecol Oncol. 2006;100:247-55.
11. Ahmed N, Oliva KT, Barker G, et al. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. Proteomics. 2005;5:4625-56.
12. Gronborg M, Kristiansen TZ, Iwahori A, et al. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics. 2006;5:157-71.
13. Melle C, Ernst G, Schimmel B, et al. Characterization of pepsinogen C as a potential biomarker for gastric cancer using a histo-proteomic approach. J Proteome Res. 2005;4:1799-804.
14. Rajapakse JC, Duan KB, Yeo WK. Proteomic cancer classification with mass spectrometry data. Am J Pharmacogenomics. 2005;5:281-92.
15. Seike M, Kondo T, Fujii K, et al. Proteomic signatures for histological types of lung cancer. Proteomics. 2005;5:2939-48.
16. Rehman A, Chahal MS, Tang X, Bruce JE, Pommier Y, Daoud SS. Proteomic identification of heat shock protein 90 as a candidate target for p55 mutation reactivation by PRIMA-1 in breast cancer cells. Breast Cancer Res. 2005;7:R765-R74.
17. Chen AL, Soman KV, Rychahou PG, Luxon BA, Evers BM. Proteomic analysis of colonic myofibroblasts and effect on colon cancer cell proliferation. Surgery. 2005; 138:382-90.
18. Hood BL, Darfler MM, Guiel TG, et al. Proteomic analysis of formalin-fixed prostate cancer tissue. Mol Cell Proteomics. 2005;4:1741-55.
19. Srivastava S, Verma M, Gopal-Srivastava, R. Proteomic maps of the cancer-associated infectious agents. J Proteome Res. 2005;4:1171-80.
20. Zhang D, Tai LK, Wong LL, Chiu LL, Sethi SK, Koay ES. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics. 2005;4:1686-96.
21. Kim J, Sun P, Lam YW, et al. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14:1697-702.
22. Yang SY, Xiao XY, Zhang WG, et al. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer. 2005;5:83.
23. Goncalves A, Esterni B, Bertucci F, et al. Postoperative serum proteomic profiles may predict metastatic relapse in highrisk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene. 2006;25:981-9.
24. Karsan A, Eigl BJ, Flibotte S, et al. Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin Chem. 2005;51: 1525-8.
25. Basso D, Greco E, Fogar P, et al. Pancretic cancer-associated diabetes mellitus: An open field for proteomic applications. Clin Chim Acta. 2005;557:184-9.
26. Alfonso P, Nunez A, Madoz-Gurpide J Lombardia L, Sánchez L, Casal JL. Proteomic expression analysis of colorectal cancer by two-dimensional differential gel electrophoresis Proteomics. 2005;5:2602-11.
27. Lee KH, Yim EK, Kim CJ, Namkoong SE, Um SJ, Park JS. Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol Oncol. 2005; 98:45-53.
28. Meyerson M, Carbone D. Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. J Clin Oncol. 2005;23:3219-26.
29. Shi P, Huang Z. Proteomic detection of changes in protein synthesis induced by lanthanum in BGC-825 human gastric cancer cells. Biometals, 2005;18:89-95.
30. Choi, YP, Kang S, Hong S, Xie X, Cho NH. Proteomic analysis of progressive factors in uterine cervical cancer. Proteomics. 2005;5:1481-93.
31. Lin B, White JT, Lu W, et al. Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: A systems approach to disease. Cancer Res. 2005;65:3081-91.
32. Alessandro R, Belluco C, Kohn EC. Proteomic approaches in colon cancer: promising tools for new cancer markers and drug target discovery. Clin Colorectal Cancer. 2005;4:396-402.
33. Benzinger A, Muster N, Koch HB, Yates JR III, Hermeking H. Targeted proteomic analysis of 14-3-5 sigma, a p55 effector commonly silenced in cancer. Mol Cell Proteomics. 2005;4:785-95.
34. Baggerly KA, Morris JS, Edmonson SR, Coombes KR. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst. 2005;97:307-9.
35. Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA. 2005; 293:810-6.
36. Chen R, Pan S, Brentnall TA, Aebersold R. Proteomic profiling of pancreatic cancer for biomarker discovery. Mol Cell Proteomics. 2005;4:523-33.
37. Posadas EM, Simpkins F, Liotta LA, MacDonald C, Kohn EC. Proteomic analysis for the early detection and rational treatment of cancer-realistic hope? Ann Oncol. 2005;16:16-22.
38. Rehman I, Azzouzi AR, Catto JW, et al. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: A pilot study. Urology. 2004;64:1238-43.
39. Alexander H, Stegner AL, Wagner-Mann C, Du Bois GC, Alexander S, Sauter ER. Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clin Cancer Res. 2004;10:7500-10.
40. Bhattacharyya S, Siegel ER, Petersen GM, Chari ST, Suva LJ, Haun RS. Diagnosis of pancreatic cancer using serum proteomic profiling. Neoplasia. 2004;6:674-86.
41. Wulfkuhle J, Espina V, Liotta L, Petricoin E. Genomic and proteomic technologies for individualisation and improvement of cancer treatment. Eur J Cancer. 2004;40:2623-32.
42. Kuerer HM, Coombes KR, Chen JN, et al. Association between ductal fluid proteomic expression profiles and the presence of lymph node metastases in women with breast cancer. Surgery. 2004;136:1061-9.
43. Chen Y, Shi G, Xia W, et al. Identification of hypoxia-regulated proteins in head and neck cancer by proteomic and tissue array profiling. Cancer Res. 2004;64:7302-10.
44. Lee K, Kye M, Jang JS, Lee OJ, Kim T, Lim D. Proteomic analysis revealed a strong association of a high level of alpha1-antitrypsin in gastric juice with gastric cancer. Proteomics. 2004;4:3543-52.
45. Dvorzhinski D, Thalasila A, Thomas PE, et al. A novel proteomic coculture model of prostate cancer cell growth. Proteomics. 2004;4:3268-75.
46. Ornstein DK, Rayford W, Fusaro VA, et al. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/m. J Urol. 2004;172:1302-5.
47. Frazier MC, Jackson KM, Jankowska-Stephens E, Anderson MG, Harris WB. Proteomic analysis of proteins altered by dibenzoylmethane in human prostatic cancer LNCaP cells. Proteomics. 2004;4:2814-21.
48. Seike M, Kondo T, Fujii K, et al. Proteomic signature of human cancer cells. Proteomics. 2004;4:2776-88.
49. Yokoo H, Kondo T, Fujii K, Yamada T, Todo S, Hirohashi S. Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells. Hepatology. 2004;40:609-17.
50. Zhang Z, Bast RC Jr, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004; 64:5882-90.
51. Wong YF, Cheung TH, Lo KW, et al. Protein profiling of cervical cancer by protein-biochips: Proteomic scoring to discriminate cervical cancer from normal cervix. Cancer Lett. 2004;211:227-34.
52. Melle C, Ernst G, Schimmel B, et al. A technical triade for proteomic identification and characterization of cancer biomarkers. Cancer Res. 2004;64:4099-104.
53. Ahmed N, Barker G, Oliva KT, et al. Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer. Br J Cancer. 2004;91:129-40.
54. Hathout Y, Gehrmann ML, Chertov A, Fenselau C. Proteomic phenotyping: metastatic and invasive breast cancer. Cancer Lett. 2004;210:245-53.
55. Euslace BK, Sakurai T, Stewart JK, et al. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol. 2004;6:507-14.
56. Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol. 2004;15:24-30.
57. Petricoin EF, Liotta LA. Proteomic approaches in cancer risk and response assessment. Trends Mol Med. 2004;10:59-64.
58. Fontana S, Pucci-Minafra I, Becchi M, Freyria AM, Minafra S. Effect of collagen substrates on proteomic modulation of breast cancer cells. Proteomics. 2004;4:849-60.
59. Roberts K, Bhatia K, Stanton P, Lord R. Proteomic analysis of selected prognostic factors of breast cancer. Proteomics. 2004; 4:784-92.
60. Alexe G, Alexe S, Liotta LA, Petricoin E, Reiss M, Hammer PL. Ovarian cancer detection by logical analysis of proteomic data. Proteomics. 2004;4:766-83.
61. Hamler RL, Zhu K, Buchanan NS, et al. A two-dimensional liquid-phase separation method coupled with mass spectrometry for proteomic studies of breast cancer and biomarker identification. Proteomics. 2004; 4:562-77.
62. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: Drawing attention to potential problems. J Natl Cancer Inst. 2004;96:353-6.
63. Kageyama S, Isono T, Iwaki H, et al. Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin Chem. 2004;50:857-66.
64. Cho WC, Yip TT, Yip C, et al. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res. 2004; 10:43-52.
65. Nishizuka S, Charboneau L, Young L, et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci USA. 2003;100:14229-34.
66. Rogers MA, Clarke P, Noble J, et al. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: Identification of key issues affecting potential clinical utility. Cancer Res. 2003;63:6971-83.
67. Verma M, Kagan J, Sidransky D, Srivastava S. Proteomic analysis of cancer-cell mitochondria. Nat Rev Cancer. 2003;3:789-95.
68. Yanagisawa K, Shyr Y, Xu BJ, et al. Proteomic patterns of tumour subsets in nonsmall-cell lung cancer. Lancet. 2003;362:433-9.
69. Yasui Y, Pepe M, Thompson ML, et al. A data-analytic strategy for protein biomarker discovery: Profiling of high-dimensional proteomic data for cancer detection. Biostatistics. 2003;4:449-63.
70. Unwin RD, Craven RA, Harnden P, et al. Proteomic changes in renal cancer and coordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics. 2003;3:1620-32.
71. Ye B, Cramer DW, Skates SJ, et al. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: Identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res. 2003;9:2904-11.
72. Varnum SM, Covington CC, Woodbury RL, et al. Proteomic characterization of nipple aspirate fluid: Identification of potential biomarkers of breast cancer. Breast Cancer Res Treat. 2003;80:87-97.
73. Banez LL, Prasanna P, Sun L, et al. Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol. 2003;170:442-6.
74. Wu SL, Hancock WS, Goodrich GG, Kunitake ST. An approach to the proteomic analysis of a breast cancer cell line (SKBR-3). Proteomics. 2003;3:1037-46.
75. Celis JE, Gromov P, Gromova I, et al. Integrating proteomic and functional genomic technologies in discovery-driven translational breast cancer research. Mol Cell Proteomics. 2003;2:369-77.
76. Sorace JM, Zhan M. A data review and reassessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics. 2003; 4:24.
77. Khan J. Genomic & proteomic technological advances in cancer research. Pharmacogenomics. 2003;4:245-9.
78. Sorace JM, Zhan M. A data review and reassessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics. 2003; 4:24.
79. Odreman F, Vindigni M, Gonzales ML, et al. Proteomic studies on low- and highgrade human brain astrocytomas. J Proteome Res. 2005;4(3):698-708.
80. Vogel TW, Zhuang Z, Li J, et al. Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme. Clin Cancer Res. 2005;11(10):3624-32.
81. Furuta M, Weil RJ, Vortmeyer AO, et al. Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene. 2004;23(40):6806-14.